AACR Names Matthew Vander Heiden, MD, PhD, FAACR, as Editor-in-Chief of the Journal Cancer Discovery
PHILADELPHIA – The American Association for Cancer Research (AACR) today announced the appointment of Matthew Vander Heiden, MD, PhD, Fellow...
Search/Filter
Loading...
AACR Releases Cancer Disparities Progress Report 2026
Report features latest statistics, including promising signs of progress, and 10 compelling personal stories PHILADELPHIA – The American Association...
Adding a Lower Cutoff Value for CA19-9 May Identify Additional High-risk Cases of Pancreatic Cancer
CA19-9 is a biomarker whose levels often correlate with pancreatic cancer stage and prognosis PHILADELPHIA – A dual-threshold model...
Emerging Frontiers in Oncology to Support AACR and Early-Career Investigators Through Annual Oncology Summit
PHILADELPHIA – The American Association for Cancer Research (AACR) today thanked Emerging Frontiers in Oncology (EFO) for its support...
Early Myocarditis Onset After Immunotherapy May Predict Treatment-related Fatality
SAN DIEGO – Patients who developed myocarditis within the first month of receiving immune checkpoint inhibitor therapy were more...
Intralesional Nivolumab May Be Effective Against Precancerous Oral Lesions
The treatment preserved quality of life SAN DIEGO – Injecting nivolumab (Opdivo) directly into precancerous oral lesions led to...
Exposure to Wildfire Smoke May Be Linked To Increased Risk of Developing Several Cancers
SAN DIEGO – Exposure to wildfire smoke was associated with a significantly increased risk of lung, colorectal, breast, bladder,...
American Association for Cancer Research Inaugurates New Leadership During AACR Annual Meeting 2026
Keith T. Flaherty, MD, FAACR, begins term as AACR President SAN DIEGO – The members of the American Association...
American Association for Cancer Research Recognizes 2025-2026 Research Grantees
PHILADELPHIA – The American Association for Cancer Research (AACR) is proud to announce its newest class of grant recipients. Since 1993, the AACR...
Distribution of Phase I Lung Cancer Trials May Be Consolidating at Top-performing U.S. Sites
SAN DIEGO – Between 2020 and 2024, the number of unique sites in the United States where phase I clinical trials for non-small cell lung cancer (NSCLC) were conducted decreased by 44% and became increasingly...